Volume 17, Number 6—June 2011
Letter
Pandemic (H1N1) 2009 and HIV Infection
Shireesha Dhanireddy
, Robert D. Harrington, Heidi M. Crane, Matthew R. Gingo, Alison Morris, Laurence Huang, and Kristina Crothers
, Robert D. Harrington, Heidi M. Crane, Matthew R. Gingo, Alison Morris, Laurence Huang, and Kristina Crothers
Table
Baseline characteristics for HIV-infected patients with pandemic (H1N1) 2009, Seattle, Washington, USA, 2009*
| Patient characteristics | All patients, n = 23 | Inpatients, n = 8 | Outpatients, n = 15 | p value† |
|---|---|---|---|---|
| Demographics | ||||
| Male sex | 19 (83) | 5 (63) | 14 (93) | 0.1 |
| Median age, y (range) | 43 (22–72) | 46 (34–72) | 42 (22–64) | 0.5 |
| Race/ethnicity | 1.0 | |||
| White | 14 (61) | 5 (63) | 9 (60) | |
| Black | 5 (22) | 2 (25) | 3 (20) | |
| Hispanic | 4 (17) | 0 | 4 (27) | 1.0 |
| Other/refused to answer |
4 (17) |
1 (13) |
3 (20) |
|
| History | ||||
| Received 2009–10 seasonal influenza vaccine before illness | 14 (61) | 6 (75) | 8 (53) | 0.1 |
| Ever smoked |
15 (65) |
7 (88) |
8 (53) |
0.2 |
| HIV-associated factors | ||||
| CD4 count, cells/µL, median (range) | 308 (32–1,024) | 147 (32–1,024) | 438 (119–833) | 0.06 |
| Undetectable HIV-1 RNA | 19 (83) | 6 (75) | 13 (87) | 0.6 |
| Receiving antiretroviral therapy |
21 (91) |
8 (100) |
13 (87) |
0.5 |
| Predisposing risk factors | 15 (65) | 6 (75) | 9 (60) | 0.5 |
| Prior lung disease | 8 (35) | 5 (63) | 3 (20) | 0.07 |
| Cardiovascular disease | 4 (17) | 3 (38) | 1 (6.7) | 0.1 |
| Obesity, body mass index >30 | 4 (17) | 1 (13) | 3 (20) | 1.0 |
| Neutropenia | 3 (13) | 2 (25) | 1 (6.7) | 0.3 |
| Receiving immunosuppressive agent | 3 (13) | 3 (38) | 0 | 0.03 |
| Malignancy | 4 (17) | 2 (25) | 2 (13) | 0.6 |
| Diabetes |
2 (8.7) |
0 |
2 (13) |
0.5 |
| Signs and symptoms | ||||
| Fever | 18 (78) | 7 (88) | 11 (73) | 0.6 |
| Fatigue | 5 (22) | 2 (25) | 3 (20) | 1.0 |
| Malaise | 11 (48) | 7 (88) | 4 (27) | 0.009 |
| Myalgia | 10 (43) | 3 (38) | 7 (47) | 1.0 |
| Sore throat | 5 (22) | 2 (25) | 3 (20) | 1.0 |
| Cough | 21 (91) | 8 (100) | 13 (87) | 0.5 |
| Dyspnea | 8 (35) | 4 (50) | 4 (27) | 0.4 |
| Nausea/vomiting | 10 (43) | 2 (25) | 8 (53) | 0.4 |
| Median duration of symptoms before seeking care, d (range) |
4 (0–30) |
4.5 (0–10) |
3 (1–30) |
0.6 |
| Physical examination findings | ||||
| Median temperature, °C (range) | 38.0 (35.7–40.2) | 39.1 (37.3–40.2) | 37.7 (35.7–38.5) | 0.001 |
| Median heart rate, beats/min (range) | 96 (69–129) | 109 (80–127) | 94 (69–129) | 0.1 |
| Mean arterial blood pressure, mm Hg (range) | 94 (66–116) | 89 (66–98) | 97 (75–116) | 0.05 |
| Median respiratory rate, breaths/min (range) | 20 (14–40) | 22 (18–40) | 19 (14–36) | 0.04 |
| Abnormal lung sounds |
11 (48) |
8 (100) |
3 (23) |
0.001 |
| Laboratory findings | ||||
| Leukocyte count, cells × 109/L (range) | 4.53 (0.53–10.8) | 3.2 (0.53–10.8) | 5.4 (2.8–9.4) | 0.4 |
| Leukopenia, <5,000 cells/µL |
9 (39) |
5 (63) |
4 (40) |
0.6 |
| Chest radiograph findings, new infiltrate |
6 (26) |
5 (63) |
1 (13) |
0.1 |
| Care received | ||||
| Antiviral treatment for influenza | 21 (91) | 8 (100) | 13 (87) | 0.5 |
| Intensive care unit admission | 3 (13) | 3 (38) | NA | |
| Mechanical ventilation | 2 (8.7) | 2 (25) | NA | |
| Vasopressors |
2 (8.7) |
2 (25) |
NA |
|
| Outcomes | ||||
| Secondary pneumonia | 3 (13) | 3 (38) | 0 | 0.03 |
| Thrombotic complications | 1 (4.6) | 1 (13) | 0 | 0.4 |
| Died | 2 (8.7) | 2 (25) | 0 | 0.1 |
*Values are no. (%) patients except as indicated. Among the 15 outpatients, 13 had a lung examination documented, 10 had a leukocyte count performed, and 8 had a chest radiograph taken. NA, not applicable.
†For comparison of characteristics between inpatients and outpatients.
Page created: August 04, 2011
Page updated: August 04, 2011
Page reviewed: August 04, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.